Extended Protection against Recurrent VTE

Kelley Branch on Treatment Strategies

© Bayer AG, 2020 | Approval number PP-XAR-ALL-0820-1

Video to Explain the Mode of Action of Venous Thrombosis

© Bayer AG, 2020 | Approval number PP-XAR-ALL-1382-1

The EINSTEIN clinical trial programme assessed the safety and efficacy of rivaroxaban compared with VKAs in patients with VTE

© Bayer AG, 2020 | Approval number PP-XAR-ALL-0092-1

Professor Paolo Prandoni looks at the role of ASA in extended VTE treatment and discusses the recent EINSTEIN CHOICE study, which compared two doses of rivaroxaban to ASA for extended VTE treatment

© Bayer AG, 2020 | Approval number PP-XAR-ALL-1747-1

Protect your patients from VTE by considering their individual risk factors and providing appropriate extended anticoagulation

© Bayer AG, 2020 | Approval number PP-M_RIVALL-0086-1

Protect your patients with cancer-associated thrombosis (CAT) with the right anticoagulant

© Bayer AG, 2020 | Approval number PP-M_RIV-ALL-0087-1